1284 related articles for article (PubMed ID: 25303717)
1. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
2. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.
Peden CS; Burger C; Muzyczka N; Mandel RJ
J Virol; 2004 Jun; 78(12):6344-59. PubMed ID: 15163728
[TBL] [Abstract][Full Text] [Related]
3. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma.
Thorsen F; Afione S; Huszthy PC; Tysnes BB; Svendsen A; Bjerkvig R; Kotin RM; Lønning PE; Hoover F
J Gene Med; 2006 Sep; 8(9):1131-40. PubMed ID: 16810631
[TBL] [Abstract][Full Text] [Related]
6. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
[TBL] [Abstract][Full Text] [Related]
7. Complement is an essential component of the immune response to adeno-associated virus vectors.
Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA
J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646
[TBL] [Abstract][Full Text] [Related]
8. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
[TBL] [Abstract][Full Text] [Related]
10. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
[TBL] [Abstract][Full Text] [Related]
13. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.
Zhang YC; Powers M; Wasserfall C; Brusko T; Song S; Flotte T; Snyder RO; Potter M; Scott-Jorgensen M; Campbell-Thompson M; Crawford JM; Nick HS; Agarwal A; Ellis TM; Atkinson MA
Gene Ther; 2004 Feb; 11(3):233-40. PubMed ID: 14737082
[TBL] [Abstract][Full Text] [Related]
14. Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5.
Sen S; Conroy S; Hynes SO; McMahon J; O'Doherty A; Bartlett JS; Akhtar Y; Adegbola T; Connolly CE; Sultan S; Barry F; Katusic ZS; O'Brien T
J Gene Med; 2008 Feb; 10(2):143-51. PubMed ID: 18067196
[TBL] [Abstract][Full Text] [Related]
15. Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.
Hammond SL; Leek AN; Richman EH; Tjalkens RB
PLoS One; 2017; 12(12):e0188830. PubMed ID: 29244806
[TBL] [Abstract][Full Text] [Related]
16. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors.
Costantini LC; Jacoby DR; Wang S; Fraefel C; Breakefield XO; Isacson O
Hum Gene Ther; 1999 Oct; 10(15):2481-94. PubMed ID: 10543613
[TBL] [Abstract][Full Text] [Related]
18. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
[TBL] [Abstract][Full Text] [Related]
19. Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors.
Sandalon Z; Bruckheimer EM; Lustig KH; Rogers LC; Peluso RW; Burstein H
J Virol; 2004 Nov; 78(22):12355-65. PubMed ID: 15507622
[TBL] [Abstract][Full Text] [Related]
20. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
